Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: Evidence of a common founder across European populations

Jennifer Kachergus, Ignacio F. Mata, Mary Hulihan, Julie P. Taylor, Sarah Lincoln, Jan Aasly, J. Mark Gibson, Owen A Ross, Timothy Lynch, Joseph Wiley, Haydeh Payami, John Nutt, Demetrius M. Maraganore, Krzysztof Czyzewski, Maria Styczynska, Zbigniew K Wszolek, Matthew J. Farrer, Mathias Toft

Research output: Contribution to journalArticle

395 Citations (Scopus)

Abstract

Autosomal dominant parkinsonism has been attributed to pathogenic amino acid substitutions in leucine-rich repeat kinase 2 (LRRK2). By sequencing multiplex families consistent with a PARX8 assignment, we identified a novel heterozygous LRRK2 mutation. A referral sample of 248 affected probands from families with autosomal dominant parkinsonism was subsequently assessed; 7 (2.8%) were found to carry a heterozygous LRRK2 6055G→A transition (G2019S). These seven patients originate from the United States, Norway, Ireland, and Poland. In samples of patients with idiopathic Parkinson disease (PD) from the same populations, further screening identified six more patients with LRRK2 G2019S; no mutations were found in matched control individuals. Subsequently, 42 family members of the 13 probands were examined; 22 have an LRKK2 G2019S substitution, 7 with a diagnosis of PD. Of note, all patients share an ancestral haplotype indicative of a common founder, and, within families, LRRK2 G2019S segregates with disease (multipoint LOD score 2.41). Penetrance is age dependent, increasing from 17% at age 50 years to 85% at age 70 years. In summary, our study demonstrates that LRKK2 G2019S accounts for parkinsonism in several families within Europe and North America. Our work highlights the fact that a proportion of clinically typical, late-onset PD cases have a genetic basis.

Original languageEnglish (US)
Pages (from-to)672-680
Number of pages9
JournalAmerican Journal of Human Genetics
Volume76
Issue number4
DOIs
StatePublished - Apr 2005

Fingerprint

Parkinsonian Disorders
Leucine
Phosphotransferases
Mutation
Parkinson Disease
Population
Penetrance
Poland
Amino Acid Substitution
Norway
North America
Ireland
Haplotypes
Referral and Consultation

ASJC Scopus subject areas

  • Genetics

Cite this

Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism : Evidence of a common founder across European populations. / Kachergus, Jennifer; Mata, Ignacio F.; Hulihan, Mary; Taylor, Julie P.; Lincoln, Sarah; Aasly, Jan; Gibson, J. Mark; Ross, Owen A; Lynch, Timothy; Wiley, Joseph; Payami, Haydeh; Nutt, John; Maraganore, Demetrius M.; Czyzewski, Krzysztof; Styczynska, Maria; Wszolek, Zbigniew K; Farrer, Matthew J.; Toft, Mathias.

In: American Journal of Human Genetics, Vol. 76, No. 4, 04.2005, p. 672-680.

Research output: Contribution to journalArticle

Kachergus, J, Mata, IF, Hulihan, M, Taylor, JP, Lincoln, S, Aasly, J, Gibson, JM, Ross, OA, Lynch, T, Wiley, J, Payami, H, Nutt, J, Maraganore, DM, Czyzewski, K, Styczynska, M, Wszolek, ZK, Farrer, MJ & Toft, M 2005, 'Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: Evidence of a common founder across European populations', American Journal of Human Genetics, vol. 76, no. 4, pp. 672-680. https://doi.org/10.1086/429256
Kachergus, Jennifer ; Mata, Ignacio F. ; Hulihan, Mary ; Taylor, Julie P. ; Lincoln, Sarah ; Aasly, Jan ; Gibson, J. Mark ; Ross, Owen A ; Lynch, Timothy ; Wiley, Joseph ; Payami, Haydeh ; Nutt, John ; Maraganore, Demetrius M. ; Czyzewski, Krzysztof ; Styczynska, Maria ; Wszolek, Zbigniew K ; Farrer, Matthew J. ; Toft, Mathias. / Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism : Evidence of a common founder across European populations. In: American Journal of Human Genetics. 2005 ; Vol. 76, No. 4. pp. 672-680.
@article{0b925ba0aeb4486aaa302201389cbea7,
title = "Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: Evidence of a common founder across European populations",
abstract = "Autosomal dominant parkinsonism has been attributed to pathogenic amino acid substitutions in leucine-rich repeat kinase 2 (LRRK2). By sequencing multiplex families consistent with a PARX8 assignment, we identified a novel heterozygous LRRK2 mutation. A referral sample of 248 affected probands from families with autosomal dominant parkinsonism was subsequently assessed; 7 (2.8{\%}) were found to carry a heterozygous LRRK2 6055G→A transition (G2019S). These seven patients originate from the United States, Norway, Ireland, and Poland. In samples of patients with idiopathic Parkinson disease (PD) from the same populations, further screening identified six more patients with LRRK2 G2019S; no mutations were found in matched control individuals. Subsequently, 42 family members of the 13 probands were examined; 22 have an LRKK2 G2019S substitution, 7 with a diagnosis of PD. Of note, all patients share an ancestral haplotype indicative of a common founder, and, within families, LRRK2 G2019S segregates with disease (multipoint LOD score 2.41). Penetrance is age dependent, increasing from 17{\%} at age 50 years to 85{\%} at age 70 years. In summary, our study demonstrates that LRKK2 G2019S accounts for parkinsonism in several families within Europe and North America. Our work highlights the fact that a proportion of clinically typical, late-onset PD cases have a genetic basis.",
author = "Jennifer Kachergus and Mata, {Ignacio F.} and Mary Hulihan and Taylor, {Julie P.} and Sarah Lincoln and Jan Aasly and Gibson, {J. Mark} and Ross, {Owen A} and Timothy Lynch and Joseph Wiley and Haydeh Payami and John Nutt and Maraganore, {Demetrius M.} and Krzysztof Czyzewski and Maria Styczynska and Wszolek, {Zbigniew K} and Farrer, {Matthew J.} and Mathias Toft",
year = "2005",
month = "4",
doi = "10.1086/429256",
language = "English (US)",
volume = "76",
pages = "672--680",
journal = "American Journal of Human Genetics",
issn = "0002-9297",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism

T2 - Evidence of a common founder across European populations

AU - Kachergus, Jennifer

AU - Mata, Ignacio F.

AU - Hulihan, Mary

AU - Taylor, Julie P.

AU - Lincoln, Sarah

AU - Aasly, Jan

AU - Gibson, J. Mark

AU - Ross, Owen A

AU - Lynch, Timothy

AU - Wiley, Joseph

AU - Payami, Haydeh

AU - Nutt, John

AU - Maraganore, Demetrius M.

AU - Czyzewski, Krzysztof

AU - Styczynska, Maria

AU - Wszolek, Zbigniew K

AU - Farrer, Matthew J.

AU - Toft, Mathias

PY - 2005/4

Y1 - 2005/4

N2 - Autosomal dominant parkinsonism has been attributed to pathogenic amino acid substitutions in leucine-rich repeat kinase 2 (LRRK2). By sequencing multiplex families consistent with a PARX8 assignment, we identified a novel heterozygous LRRK2 mutation. A referral sample of 248 affected probands from families with autosomal dominant parkinsonism was subsequently assessed; 7 (2.8%) were found to carry a heterozygous LRRK2 6055G→A transition (G2019S). These seven patients originate from the United States, Norway, Ireland, and Poland. In samples of patients with idiopathic Parkinson disease (PD) from the same populations, further screening identified six more patients with LRRK2 G2019S; no mutations were found in matched control individuals. Subsequently, 42 family members of the 13 probands were examined; 22 have an LRKK2 G2019S substitution, 7 with a diagnosis of PD. Of note, all patients share an ancestral haplotype indicative of a common founder, and, within families, LRRK2 G2019S segregates with disease (multipoint LOD score 2.41). Penetrance is age dependent, increasing from 17% at age 50 years to 85% at age 70 years. In summary, our study demonstrates that LRKK2 G2019S accounts for parkinsonism in several families within Europe and North America. Our work highlights the fact that a proportion of clinically typical, late-onset PD cases have a genetic basis.

AB - Autosomal dominant parkinsonism has been attributed to pathogenic amino acid substitutions in leucine-rich repeat kinase 2 (LRRK2). By sequencing multiplex families consistent with a PARX8 assignment, we identified a novel heterozygous LRRK2 mutation. A referral sample of 248 affected probands from families with autosomal dominant parkinsonism was subsequently assessed; 7 (2.8%) were found to carry a heterozygous LRRK2 6055G→A transition (G2019S). These seven patients originate from the United States, Norway, Ireland, and Poland. In samples of patients with idiopathic Parkinson disease (PD) from the same populations, further screening identified six more patients with LRRK2 G2019S; no mutations were found in matched control individuals. Subsequently, 42 family members of the 13 probands were examined; 22 have an LRKK2 G2019S substitution, 7 with a diagnosis of PD. Of note, all patients share an ancestral haplotype indicative of a common founder, and, within families, LRRK2 G2019S segregates with disease (multipoint LOD score 2.41). Penetrance is age dependent, increasing from 17% at age 50 years to 85% at age 70 years. In summary, our study demonstrates that LRKK2 G2019S accounts for parkinsonism in several families within Europe and North America. Our work highlights the fact that a proportion of clinically typical, late-onset PD cases have a genetic basis.

UR - http://www.scopus.com/inward/record.url?scp=20144387207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144387207&partnerID=8YFLogxK

U2 - 10.1086/429256

DO - 10.1086/429256

M3 - Article

C2 - 15726496

AN - SCOPUS:20144387207

VL - 76

SP - 672

EP - 680

JO - American Journal of Human Genetics

JF - American Journal of Human Genetics

SN - 0002-9297

IS - 4

ER -